Form 4: Ultragenyx EVP Crombez Sells Shares to Cover Tax Obligations

Eric Crombez, EVP and Chief Medical Officer of Ultragenyx Pharmaceutical Inc., sold 354 shares of common stock on May 2, 2024, to cover tax withholdings related to vesting RSUs.

Summary

• On May 2, 2024, Eric Crombez, the EVP and Chief Medical Officer of Ultragenyx Pharmaceutical Inc., sold 354 shares of the company's common stock.
• The shares were sold at a price of $43.66 per share.
• The transaction was executed to cover required tax withholdings due to the vesting of Restricted Stock Units (RSUs).
• Following the transaction, Crombez beneficially owns 48,431 shares of Ultragenyx common stock, which includes shares underlying previously granted RSUs subject to vesting conditions.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to an insider stock sale for tax purposes, which is a neutral event.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

Form 4 filings are routine disclosures required by the SEC when company insiders, like Eric Crombez, trade their company's stock. These filings provide transparency into insider transactions, allowing investors to see if those with inside knowledge of the company are buying or selling shares. It is common for executives to sell shares to cover tax obligations when RSUs vest.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to have a significant effect given the reason for the sale.

Key Dates